UBS Asset Management Americas Inc. Increases Stock Position in G1 Therapeutics, Inc. (NASDAQ:GTHX)

UBS Asset Management Americas Inc. raised its position in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) by 7.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,011 shares of the company’s stock after buying an additional 2,899 shares during the quarter. UBS Asset Management Americas Inc. owned about 0.10% of G1 Therapeutics worth $900,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Fisher Asset Management LLC purchased a new position in shares of G1 Therapeutics in the 2nd quarter worth about $20,072,000. Morgan Stanley raised its position in shares of G1 Therapeutics by 142.0% in the 2nd quarter. Morgan Stanley now owns 572,061 shares of the company’s stock worth $12,551,000 after purchasing an additional 335,635 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of G1 Therapeutics by 166.7% in the 2nd quarter. Point72 Asset Management L.P. now owns 399,844 shares of the company’s stock worth $8,773,000 after purchasing an additional 249,908 shares during the last quarter. Tekla Capital Management LLC raised its position in shares of G1 Therapeutics by 59.4% in the 2nd quarter. Tekla Capital Management LLC now owns 624,369 shares of the company’s stock worth $13,699,000 after purchasing an additional 232,615 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of G1 Therapeutics by 26.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,070,124 shares of the company’s stock worth $23,480,000 after purchasing an additional 225,057 shares during the last quarter. 64.04% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on GTHX shares. Roth Capital lowered their price target on G1 Therapeutics from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Wednesday, November 3rd. JPMorgan Chase & Co. lowered G1 Therapeutics from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $20.00 to $19.00 in a research report on Thursday, November 4th. HC Wainwright decreased their target price on G1 Therapeutics from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, November 4th. Raymond James decreased their target price on G1 Therapeutics from $41.00 to $24.00 and set an “outperform” rating for the company in a research report on Thursday, November 4th. Finally, Wedbush decreased their target price on G1 Therapeutics from $59.00 to $38.00 and set an “outperform” rating for the company in a research report on Thursday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $42.43.

G1 Therapeutics stock opened at $13.66 on Thursday. The business has a 50-day simple moving average of $14.07 and a two-hundred day simple moving average of $17.07. The company has a market cap of $580.85 million, a P/E ratio of -4.19 and a beta of 2.16. G1 Therapeutics, Inc. has a 52-week low of $11.98 and a 52-week high of $37.07. The company has a quick ratio of 8.63, a current ratio of 8.68 and a debt-to-equity ratio of 0.17.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, November 3rd. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.03) by $0.03. G1 Therapeutics had a negative return on equity of 65.66% and a negative net margin of 316.58%. During the same quarter in the prior year, the company posted ($0.31) earnings per share. Research analysts anticipate that G1 Therapeutics, Inc. will post -3.62 EPS for the current fiscal year.

About G1 Therapeutics

G1 Therapeutics, Inc engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Further Reading: How to Invest in Stocks with Increasing Dividends

Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics, Inc. (NASDAQ:GTHX).

Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.